Select your country

Websites worldwide

Select a country to go to the website of the respective STADA sales company.

Belarus (1)

Belgium (1)

Bosnia-Herzegovina (1)

Bulgaria (1)

Croatia (1)

Denmark (1)

Hungary (1)

Italy (1)

Montenegro (1)

Portugal (1)

Romania (1)

Saudi Arabia (1)

Serbia (1)

Slovenia (1)

Switzerland (1)

United Arab Emirates (1)

STADA - Caring for People's Health

A message from Peter Goldschmidt, CEO

I am immensely proud of the group’s outstanding performance in 2023.
Against a backdrop of geopolitical conflicts and economic challenges, we were able to maintain our double-digit growth trend based on our unique culture.

This performance fully in line with our corporate vision, shows the benefit of having a consistent strategy that has delivered sustained strong growth over several years.

Above all, our ability to maintain double-digit sales and profit growth from continuing operations is down to one thing: the extraordinary dedication and expertise of our around 11,700 employees worldwide. Put simply, our unique culture drove our outstanding performance in 2023.

"Our success is based on our culture and our purpose of
Caring for People’s Health as a Trusted Partner."



Peter Goldschmidt signature

STADA has outperformed its competitors

Group sales 2023 (adjusted)
€ 3,734.8 million

EBITDA 2023 (adjusted)
€ 802,0 million

Number of licensing deals
in 2023

On Time In Full supplies

Packages sold

of the global pharma
companies on ESG

worldwide (on average -
based on FTE) + 8%

Women in leadership positions

employee satisfaction score

Culture drives Performance

Alongside our purpose, STADA’s growth and competitive advantage is based on its unique culture, guided by the values of Integrity, Entrepreneurship, Agility and One STADA. The deep purpose-driven engagement of its employees makes STADA the place to be.

Worldwide (on average - based on FTE) + 8%

Women in leadership positions

Employee satisfaction score

STADA is proud to be among the most sustainable pharmaceutical companies globally.

This independent assessment reflects the group’s commitment to working as a trusted partner with customer, regulator and capital market stakeholders to ensure that STADA has sound foundations for sustained success.

Consistent with its own areas of business, company purpose, and values, STADA supports the implementation of the following SDGs:

STADA has become the market leader in Consumer Healthcare in Germany. The company has also secured market leadership in Serbia and ranks second in Belgium. Sales in France, Italy and Spain also grew strongly during the past financial year. This makes STADA the fourth-largest Consumer Healthcare company in Europe.

Generics: Enabling affordable access

Generic medicines make an important contribution to ensuring that patients all over the world have access to high-quality, affordable medicines. As a leading supplier of generics, STADA plays a key role in supporting health systems around the world.
Containing the same active ingredient at the same dose as an original reference medicine, and manufactured according to the same quality standards as all other medicines, generics enable a wide range of diseases and healthcare conditions to be treated at a fraction of the cost of original medicines.

Specialty: serving specific patient needs

As STADA’s fastest-growing product segment in 2023, Specialty is an increasingly essential element of the group’s growth strategy.
Specialty Pharmaceuticals serve specific needs of patients and their caregivers. By developing and supplying these medicines that are typically prescribed and administered by specialist doctors for chronic, complex, severe or rare diseases, the Specialty segment is central to STADA’s purpose of Caring for People’s Health as a Trusted Partner.


Such therapies include biological medicines that usually require cold-chain storage and administration via injection or infusion; device-aided therapies such as on body pumps, pre-filled syringes or autoinjector pens; and ‘orphan’ medicines authorized for treating rare diseases that require specialist treatment.

One STADA story – writing the next chapter

STADA Production sites – keep supplying medicines


United Kingdom










Bad Vilbel






Tuy Hoa (PME1 and PME2)



Bosnia and Herzegovina

Banja Luka







Czech Republic










Bila Tserkva

STADA Annual Report 2023